Teva Pharmaceutical Industries Ltd.'s new CSO and president of
global R&D, Michael Hayden, plans to break down the silos
housing generics and branded R&D with the aim of improving both
businesses while better serving a global patient population.  He
also has designs on increasing in-house discovery and
personalized medicines efforts, and on opening up the
organization to more innovative partnering.